Art. -Nr.: HY-100851A

LY-272015 hydrochloride

Name: LY-272015 hydrochloride
Brand: MedChemExpress
SKU: HY-100851A
Price: 125.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Kundenbewertung

Based on 1 Customer Validation

LY-272015 hydrochloride is an orally active and selective 5-HT_2B receptor antagonist. LY-272015 hydrochloride blocks 5-HT₂ receptors and inhibits Fluoxetine (HY-B0102)-induced PDGFβ receptor transactivation. LY-272015 hydrochloride attenuates 5-HT-induced smooth muscle cell migration and proliferation, and inhibits downstream mTOR/p70S6K phosphorylation. LY-272015 hydrochloride reduces 5-HT-induced vasoconstriction. LY-272015 hydrochloride reverses the excitatory effect of BW-723C86 (HY-101369) on NTS neurons. LY-272015 hydrochloride lowers mean arterial blood pressure in severely hypertensive DOCA-salt rats. LY-272015 hydrochloride can be used in research related to diseases such as hypertension and cardiovascular calcification.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.89%
CAS. Nr.: 172895-15-7
Formel: C₂₁H₂₅ClN₂O₂
Molecular Weight:372.89

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

LY-272015 hydrochloride Chemical Structure

CAS. Nr.: 172895-15-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]

5-HT_2B Receptor

PDGFRβ

mTOR

Alle 5-HT Receptor Isoform-spezifische Produkte anzeigen :

Alle mTOR Isoform-spezifische Produkte anzeigen :

Alle PDGFR Isoform-spezifische Produkte anzeigen :

In Vitro

LY-272015 (LY) (0-5 μM; 5 min) hydrochloride inhibits Fluoxetine (HY-B0102)-induced PDGFβ receptor transactivation in SH-SY5Y cells^[1].
LY-272015 (100 nmol/L; 0-24 h) hydrochloride attenuates 5-HT-induced migration and proliferation of rat aortic SMCs^[2].
LY-272015 (10 nmol/L; 2 h) hydrochloride antagonizes 5-HT-induced activation of the mTOR/p70S6K pathway in rat aortic SMCs^[2].
LY 272015 (2.87 μg/mL; 5 min) hydrochloride had no significant effect on the amplitude or frequency of phrenic nerve discharge in isolated perfused brainstem preparations from Sprague-Dawley rats^[3].
LY-272015 hydrochloride right-shifted the BW-723C86 (HY-101369)-induced contraction curve in endothelium-denuded mesenteric arteries of DOCA-salt rats, confirming the involvement of vascular 5-HT_2B receptors in the increase^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cardiovascular RegulationLocal Vascular RegulationRegulation of Cardiac Pump Function

Cardiovascular Regulation

Local Vascular Regulation

LY-272015 (0.3-3 mg/kg; intravenous injection; once weekly; for 4 weeks) hydrochloride significantly reduced mean arterial blood pressure in severely hypertensive DOCA-salt rats^[4].

Regulation of Cardiac Pump Function

LY-272015 (30-50 nA) hydrochloride reverses the excitatory effect of BW-723C86 on active Group 2 and Group 3 (active and inactive) NTS neurons, but does not reverse the inhibitory effect of BW-723C86 on inactive Group 2 cells^[5].

Regulation of Cardiac Pump Function

Local Vascular Regulation

LY-272015 (3 mg/kg; intraperitoneal injection; 3 days per week; 8 weeks) hydrochloride did not inhibit the progression of aortic calcification or reduce atherosclerotic lipid/lesion area in diet-induced calcific atherosclerosis Apoe^−/− mice, and did not affect bone density^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Chemical Information

CAS. Nr. 172895-15-7
Appearance Solid
Molecular Weight 372.89
Formel C₂₁H₂₅ClN₂O₂
Color Off-white to light yellow
SMILES

CC1=CC2=C(NC3=C2CCNC3CC4=CC=C(OC)C(OC)=C4)C=C1.[H]Cl
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 5 mg/mL (13.41 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6818 mL

13.4088 mL

26.8176 mL

5 mM

0.5364 mL

2.6818 mL

5.3635 mL

10 mM

0.2682 mL

1.3409 mL

2.6818 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (292 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Kruk JS, et al. Fluoxetine-induced transactivation of the platelet-derived growth factor type β receptor reveals a novel heterologous desensitization process. Molecular and cellular neurosciences. 2015 Mar;65:45-51.

[2]. Liu Y. Inhibition of 5‐Hydroxytryptamine Receptor 2B Reduced Vascular Restenosis and Mitigated the β‐Arrestin2–Mammalian Target of Rapamycin/p70S6K Pathway. Journal of the American Heart Association. 2018 Jan 30;7(3):e006810.

[3]. Niebert M. Expression and function of serotonin 2A and 2B receptors in the mammalian respiratory network. PLoS One. 2011 Jul 18;6(7):e21395.

[4]. Watts SW, et al. 5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats. The American journal of physiology. 1999 Mar;276(3):H944-52. [Content Brief]

[5]. Sévoz-Couche C, et al. In vivo modulation of vagal-identified dorsal medullary neurones by activation of different 5-Hydroxytryptamine(2) receptors in rats. Br J Pharmacol. 2000 Dec;131(7):1445-53.

[6]. Hon A, et al. Specific serotonin receptor antagonist reduces murine calcific atherosclerosis. Atherosclerosis. 2026 Mar;414:120649.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6818 mL	13.4088 mL	26.8176 mL	67.0439 mL
	5 mM	0.5364 mL	2.6818 mL	5.3635 mL	13.4088 mL
	10 mM	0.2682 mL	1.3409 mL	2.6818 mL	6.7044 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

LY-272015 hydrochloride

Alle 5-HT Receptor Isoform-spezifische Produkte anzeigen

Alle mTOR Isoform-spezifische Produkte anzeigen

Alle PDGFR Isoform-spezifische Produkte anzeigen